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Editorial
Pulmonary  arterial  hypertension  due  to  pulmonary
veno-occlusive disease  in  systemic  sclerosis:
Importance of  early  diagnosis  and  cautious  use  of
pulmonary vasodilator  therapy
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of Cardiology  Cases  described  a  typical  case  of  SSc-PAH
due to  PVOD  and  gives  us  the  important  message  toKEYWORDS
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Pulmonary arterial  hypertension  (PAH)  is  a  serious  and
life-threatening condition  characterized  by  pulmonary  vas-
cular  remodeling  leading  to  increased  pulmonary  arterial
pressure and  subsequent  right  ventricular  failure  and  death.
It can  be  idiopathic  (IPAH),  heritable,  and  caused  by  various
underlying conditions  including  connective  tissue  diseases,
mostly systemic  sclerosis  (SSc;  scleroderma)  [1].  Signiﬁcant
advancements in  the  ﬁeld  of  PAH  with  regard  to  genetic,
molecular, and  cellular  mechanisms  have  been  made  over
the past  quarter  of  a  century,  which  have  led  to  a  number
of targeted  therapies  acting  on  distinct  pathways  and  have
improved the  symptoms,  exercise  capacity,  and  possibly
prognosis in  patients  with  PAH.  Pulmonary  veno-occlusive
disease (PVOD)  is  a  rare  form  of  PAH  accounting  for  5—10%
of initially  diagnosed  IPAH,  and  pathologically  characterized
by ﬁbrotic  obliteration  of  predominantly  the  venules  and
small veins  in  the  interlobular  septa  of  the  pulmonary
vasculature sparing  the  larger  veins  [2,3].  Although  PVOD
shares similar  clinical  presentation,  genetic  background,
and hemodynamic  characteristics  with  PAH,  the  prognosis
is worse  compared  with  IPAH  and  severe  pulmonary  edema
can develop  with  a  novel  PAH-speciﬁc  therapy  [4].  PVOD
is classiﬁed  in  a  separate  but  related  group  of  PAH  as
t
d
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doi:10.1016/j.jccase.2012.03.001roup  1′ together  with  pulmonary  capillary  hemangiomato-
is (PCH)  [1].
SSc  is  a  connective  tissue  disease  of  unknown  etiology
haracterized by  microvasculopathy,  progressive  ﬁbrosis  of
he skin  and  various  internal  organs,  and  immune  abnormal-
ty. SSc-associated  PAH  (SSc-PAH)  caused  by  immune  related
asculitis of  the  pulmonary  vasculature  and  secondary  to
nterstitial lung  disease  and  left-sided  heart  failure  mainly
y diastolic  dysfunction  due  to  left  ventricular  ﬁbrosis,
ccurs in  7—12%  of  patients  with  SSc.  Compared  with  IPAH,
Sc-PAH has  a  signiﬁcantly  inferior  response  to  PAH-speciﬁc
herapy and  much  worse  prognosis  and  is  the  leading  cause
f death  together  with  pulmonary  ﬁbrosis  in  SSc  [5].  As
ife-threatening acute  pulmonary  edema  is  reported  as  a
omplication of  vasoactive  treatment  in  SSc-PAH  as  for
VOD, venular  remodeling  may  similarly  characterize  SSc-
AH. Overbeek  analyzed  lung  tissues  from  8  patients  with
Sc-PAH, and  all  had  both  arterial  and  venous  remodel-
ng and  4  out  of  8  patients  displayed  a  PVOD-like  pattern
6]. Another  study  showed  6  out  of  8  patients  with  con-
ective tissue  disease-associated  PAH  (CTD-PAH),  including
ll 4  patients  with  SSc-PAH,  had  PVOD-like  lesions  in  their
ung specimens  [7].  Fibrous  remodeling  within  pulmonary
eins and  venules  may  develop  by  altered  ﬁbrous  reaction
atterns, one  of  which  is  an  altered  transforming  growth
actor- pathway  signaling,  of  the  post-capillary  vasculature
8].
A recent  report  by  Tada  et  al.  [9]  in  the  Journalake care  of  the  patients  with  these  conditions.  They
escribed a  55-year-old  female  with  SSc-PAH  introduced
Ltd.   Open access under CC BY-NC-ND license.
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or  treatment  with  intravenous  epoprostenol  because  of
he worsening  symptoms  even  after  aggressive  treatment
ith pulmonary  vasodilators,  including  oral  prostaglandin,
ndothelin receptor  antagonists,  and  phosphodiesterase  5
nhibitors at  a  prior  medical  facility.  After  administration
f intravenous  epoprostenol,  pulmonary  edema  appeared
ose-dependently and  the  presence  of  PVOD  was  suspected
t that  time.  High  resolution  computed  tomography  (HRCT)
f the  chest  showed  septal  line  thickening  and  centrilobular
round-glass opacities  which  are  relatively  speciﬁc  ﬁndings
f PVOD.  Along  with  reduction  of  epoprostenol  infusion  her
ulmonary edema  disappeared  gradually.  She  refused  to
ave a  lung  transplantation  and  died  4  months  later  after
he introduction  of  intravenous  epoprostenol  therapy.  A  his-
ological examination  revealed  severe  stenosis  and  occlusion
f pulmonary  veinules  and  small  veins  as  well  as  pulmonary
rterial and  capillary  components.  This  report  suggests  that
arly diagnosis  of  PVOD  is  important  to  avoid  a  vicious  effect
ike acute  pulmonary  edema  as  a  result  of  PAH-speciﬁc
asodilator therapy.
The  deﬁnite  diagnosis  of  PVOD,  however,  needs
istopathological  conﬁrmation  of  a  wide  spread  ﬁbrous  inti-
al proliferation  predominantly  involved  in  the  pulmonary
enules and  small  veins  by  surgical  lung  biopsy,  but  lung
iopsy is  not  recommended  in  patients  with  PAH  because  of
ssociated signiﬁcant  risk.  Alternatively,  integrated  assess-
ent of  clinical  backgrounds  like  a  higher  male/female
atio and  higher  tobacco  exposure  in  PVOD  compared  with
PAH, and  noninvasive  examination  may  be  helpful  [10].
atients with  PVOD  show  signiﬁcantly  lower  resting  partial
ressure of  arterial  oxygen  (PaO2),  a  lower  nadir  arterial
xygen saturation  (SaO2)  during  6  min  walk  test,  and  a
ower single-breath  diffusing  capacity  for  carbon  monoxide
DLCO) compared  with  patients  with  IPAH  [2,3,10].  HRCT
f the  chest  is  an  important  diagnostic  imaging  modality  to
valuate suspected  PVOD.  Beside  the  ﬁndings  of  hemody-
amic consequences  of  PAH  like  central  pulmonary  arterial
nlargement, right  ventricular  hypertrophy  and  dilatation,
nd bowing  of  the  interventricular  septum,  normal  sized
eft-sided cardiac  chambers  and  main  pulmonary  veins  are
een. A  triad  of  diffuse  ground-glass  opaciﬁcation,  espe-
ially in  centrilobular  distribution,  septal  line  thickening,
nd enlargement  of  mediastinal  lymph  node  are  highly  sug-
estive ﬁndings  of  PVOD  in  patients  with  suspected  PAH
10,11]. These  ﬁndings  reﬂect  the  increasing  hydrostatic
ressure in  pulmonary  capillary  and  the  pulmonary  venules
r small  veins  component,  and  congestion  of  the  lymphatic
ow without  the  left-sided  heart  disease.  Bronchoalveolar
avage (BAL)  by  bronchoscopy  may  be  helpful  for  diagnosing
VOD. Signiﬁcantly  increased  numbers  of  hemosiderin-laden
acrophages are  seen  and  there  is  higher  average  Gold
core, which  means  occult  alveolar  hemorrhage  is  relatively
ommon in  PVOD  [12].  However,  bronchoscopy  is  a  rela-
ively invasive  technique  with  an  unacceptably  high  rate  of
omplications and  not  recommended  in  patients  with  this
ondition.
Although right  heart  catheterization  is  an  important
odality to  conﬁrm  the  diagnosis  of  pulmonary  hyperten-ion by  a  mean  pulmonary  arterial  pressure  (PAP)  more
han 25  mmHg,  and  estimate  the  severity  of  hemodynamic
isorder, it  cannot  distinguish  PVOD  from  PAH,  because
easured pulmonary  capillary  wedge  pressure  (PCWP)
e
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alues  are  normal  range  (less  than  15  mmHg)  in  PVOD,
nd there  are  characteristic  ﬁndings  of  precapillary  pul-
onary hypertension,  even  though  anatomical  obstruction
n PVOD  is  predominantly  at  postcapillary  sites.  This  dis-
repancy is  caused  by  the  way  of  measuring  the  PCWP.
he site  of  the  wedged  catheter  with  inﬂated  balloon
s at  relatively  large  branches  of  the  pulmonary  arter-
es, and  the  measured  pressure  at  that  site  reﬂects  the
ressure at  counterpart  of  the  same  size  of  pulmonary
eins, which  have  no  obstruction  and  normal  pressure
2,3].
Despite discoveries  of  new  speciﬁc  PAH  therapies,  such
s intravenous  prostacyclin,  prognosis  of  PVOD  remains
oor and  currently  lung  or  combined  heart—lung  transplan-
ation seems  the  only  therapeutic  alternative  to  bring  a
urable clinical  improvement  and  a  possible  survival  ben-
ﬁt. Therefore,  early  referral  for  transplant  evaluation  is
ecommended. The  waiting  time  for  transplantation,  how-
ver, may  exceed  a  limited  expected  survival  in  PVOD.
lthough a life-threatening  acute  pulmonary  edema  caused
y PAH-speciﬁc  vasodilator  therapy  in  PVOD  is  notable,  a
autious use  of  continuous  intravenous  epoprostenol  at  low
ose ranges  and  slow  dose  increases  with  high-dose  diuretics
mproved clinical  and  hemodynamic  parameters  in  PVOD  at
—4 months  without  commonly  causing  pulmonary  edema,
nd may  be  a  useful  bridge  to  urgent  lung  transplantation
13]. Successful  management  using  single  drug  regimens  of
osentan (a  non-selective  endothelin  antagonist)  and  silde-
aﬁl (a  selective  inhibitor  of  phosphdiesterase  type-5)  in
are cases  of  PVOD  have  been  described.  But  a  poten-
ial increased  risk  of  acute  pulmonary  edema  restricted
he use  of  these  drugs  at  the  specialized  expert  cen-
er. Even  though  ﬁrst-line  monotherapy  is  not  complicated
ith pulmonary  edema,  use  of  combinations  of  PAH-speciﬁc
gents in  a  goal-oriented  strategy  should  be  undertaken
ith caution  in  PVOD  [14].  Although  treatment  with  the
latelet-derived growth  factor  receptor  inhibitor  imatinib,
hich has  anti-proliferative  effects  on  pulmonary  vascular
mooth muscle  cells,  resulted  in  rapid  clinical  improve-
ent and  decrease  of  ground-glass  opacities  and  septal
hickening on  HRCT  in  PVOD  [15],  imatinib  still  has  an
xperimental status  and  should  not  be  used  outside  refer-
nce centers.  Successful  outcomes  of  immunosuppressive
herapies for  PAH  complicated  with  sarcoidosis,  systemic
upus erythematosus,  and  mixed  connective  tissue  disease
ave been  reported  but  no  signiﬁcant  effects  were  seen  in
Sc-PAH. Conventional  general  measures,  limitation  of  phys-
cal activity,  supplemental  oxygen,  vaccinations  to  prevent
neumococcal pneumonia  and  inﬂuenza,  smoking  cessation,
arfarin anticoagulation  with  caution  due  to  occult  alveolar
emorrhage, and  effective  contraception  for  child-bearing
emales, may  be  recommended.  Montani  from  the  French
eferral Center  for  Pulmonary  Hypertension  offers  a  real-
stic algorithm  for  managing  PVOD  at  the  present  time
Fig. 1)  [3].
Despite  the  advent  of  novel  PAH-speciﬁc  therapies,  prog-
osis of  PVOD  is  still  dismal.  Early  diagnosis  of  PVOD  with
he noninvasive  modalities  in  patients  with  suspected  PAH,
specially SSc-PAH,  before  trying  vasodilator  therapies  and
autious use  of  some  PAH-speciﬁc  therapies  as  a  bridge  to
ung transplantation  may  be  the  acceptable  measures  to
anage PVOD  currently.
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Figure  1  Management  of  pulmonary  veno-occlusive  disease  (PVOD)  at  the  French  Referral  Center  for  Pulmonary  Hypertension.
Reprinted, with  permission,  from  Montani  et  al.  [3].  PAH,  pulmonary  arterial  hypertension;  mPAP,  mean  pulmonary  arterial  pressure;
PCWP,  pulmonary  capillary  wedge  pressure;  PFT,  pulmonary  function  test;  PaO2,  arterial  oxygen  tension;  DLCO,  diffusion  capacity
of  the  lung  for  carbon  monoxide;  SpO2,  arterial  oxygen  saturation  measured  by  pulse  oxymetry;  6-MWT,  6  min’  walk  test;  HRCT,
high  resolution  computed  tomography;  BAL,  bronchoalveolar  lavage;  NYHA,  New  York  Heart  Association;  IPDE5,  phosphodiesterase
type-5 inhibitor;  ERA,  endothelin  receptor  antagonist.
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